Company intelligence / Profile preview

IKOMED Technologies

Vancouver, British Columbia, Canadaikomed.com ↗

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

The AEGIS system has been FDA cleared and shown to reduce X-ray radiation in fluoroscopy by over 60% in clinical studies. It is commercially available in the USA through a partnership with Omega Medical Imaging. The ATMOS device has demonstrated efficacy in early preclinical testing and ongoing in vivo studies, targeting noninvasive treatment of emphysema.

Therapeutic areas: OtherPulmonology
Modalities: DeviceAI-guided imaging systemRadiofrequency-based therapy
Industry: Medical Imaging

Partnerships

Omega Medical Imaging (commercialization partner for AEGIS)

Beyond the preview

Go deeper on IKOMED Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IKOMED Technologies.

Explore the full profile